Ondansetron in the Prevention of Hypotension in Patients Undergoing Spinal Anesthesia

• Status: Unknown status
• Trial end date: 2020-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Ondansetron, a potent 5-HT 3 receptor antagonist commonly used as an antiemetic. The main objective of the present study is to verify the hypothesis that blocking type 3 serotonin receptors with intravenous ondansetron reduces the incidence of spinal anesthesia-induced hypotension

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Hospital de Base
• Treatments: Anesthetics; Ondansetron

Criteria

Inclusion Criteria:

• Patients aged between 18 and 70 years, electively scaled for surgery requiring neuraxial block, with programming of spinal anesthesia.

• Physical State 1, 2 or 3 of the American Society of Anesthesiology (ASA)

Exclusion Criteria:

• Patients taking prophylactic or therapeutic anticoagulation, except respecting the allowed range;

• Patients with atrioventricular block

• Patients with cardiac arrhythmias

• Patients with heart failure;

• Patients with renal disease

• Patients with liver disease

• Patient carrying or suspecting any type of systemic infection or located in a puncture site;

• Patients who refuse to participate in the study after presenting the free and informed consent form;